...
首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Qualitative and quantitative studies on impurities in G004, a potential hypoglycaemic agent, using liquid chromatography, nuclear magnetic resonance and mass spectrometry.
【24h】

Qualitative and quantitative studies on impurities in G004, a potential hypoglycaemic agent, using liquid chromatography, nuclear magnetic resonance and mass spectrometry.

机译:使用液相色谱,核磁共振和质谱法对潜在的降血糖药G004中的杂质进行定性和定量研究。

获取原文
获取原文并翻译 | 示例
           

摘要

G004, 1-(4-(2-(4-bromobenzenesulphonamino) ethyl) phenylsuphonyl)-3-(trans-4-methylcyclohexyl) urea, is being developed as a potential hypoglycaemic agent. In this study, the related compounds in the bulk drug substance of G004 were analyzed both qualitatively and quantitatively. An unknown compound in the drug, which has never been reported, was isolated using preparative liquid chromatography and characterized as 1-(4-(2-(2-bromobenzenesulphonamino) ethyl) phenylsuphonyl)-3-(trans-4-methylcyclohexyl) urea using nuclear magnetic resonance and mass spectrometry. Moreover, a reversed-phase liquid chromatography method was developed for quantification of both the major impurities and the main constituent. The proposed method was validated and applied during impurity studies and quality control analysis of the bulk drug and laboratory-prepared samples of G004.
机译:G004,1-(4-(2-(4-溴苯磺酰胺基)乙基)苯磺酰基)-3-(反式-4-甲基环己基)脲,正在开发作为一种潜在的降血糖药。本研究对G004原料药中的相关化合物进行了定性和定量分析。该药物中未知的化合物(从未报道过)使用制备型液相色谱法进行了分离,并表征为1-(4-(2-(2-溴苯磺酰胺基)乙基)苯磺酰基)-3-(反式-4-甲基环己基)脲使用核磁共振和质谱。此外,开发了一种反相液相色谱法,用于定量分析主要杂质和主要成分。该方法在大药和实验室制备的G004样品的杂质研究和质量控制分析中得到了验证和应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号